2024
1199-P: Tackling Transition of Care of Young Adults with Type 1 Diabetes—Preliminary Findings
DIAS A, CONSIDINE E, WEYMAN K, CARR D, TICHY E, SHERR J. 1199-P: Tackling Transition of Care of Young Adults with Type 1 Diabetes—Preliminary Findings. Diabetes 2024, 73 DOI: 10.2337/db24-1199-p.Peer-Reviewed Original ResearchYoung adultsYale-New Haven Children's HospitalAdult providersKnowledge deficitsStructured visitsFeasibility studyTertiary care centerT1D durationCare centerReproductive healthRe-administeredChildren's HospitalAdultsProspective studyVisitsImpact of substancesMultidisciplinary approachDiabetesPre-transition periodTarget glycemiaProvidersHealthHospitalParticipantsSocial work326-OR: Activity Feature Attenuates Drop in Glucose for Individuals with Type 1 Diabetes Using Omnipod 5 Automated Insulin Delivery System
TURNER L, SHERR J, ZAHARIEVA D, BARAN J, BODE B, BROWN S, BZDICK S, MEI CHURCH M, HANSEN D, KINGMAN R, LAFFEL L, SHAH V, STONE S, VIENNEAU T, HUYETT L, DUMAIS B, LY T, RIDDELL M, 5 EXERCISE RESEARCH GROUP O. 326-OR: Activity Feature Attenuates Drop in Glucose for Individuals with Type 1 Diabetes Using Omnipod 5 Automated Insulin Delivery System. Diabetes 2024, 73 DOI: 10.2337/db24-326-or.Peer-Reviewed Original ResearchGeneralized estimating equationsInternational Society for Pediatric and Adolescent DiabetesActivity sessionsEstimating equationsType 1 diabetesExerciseAdolescent DiabetesAF-30Glucose declineDeliveryInsulin deliveryInsuletSessionsDelivery systemInsulin delivery systemsDiabetesAutomated deliveryOmnipodRiskGlucoseT1DPeople
2023
Utility and precision evidence of technology in the treatment of type 1 diabetes: a systematic review
Jacobsen L, Sherr J, Considine E, Chen A, Peeling S, Hulsmans M, Charleer S, Urazbayeva M, Tosur M, Alamarie S, Redondo M, Hood K, Gottlieb P, Gillard P, Wong J, Hirsch I, Pratley R, Laffel L, Mathieu C. Utility and precision evidence of technology in the treatment of type 1 diabetes: a systematic review. Communications Medicine 2023, 3: 132. PMID: 37794113, PMCID: PMC10550996, DOI: 10.1038/s43856-023-00358-x.Peer-Reviewed Original ResearchType 1 diabetesTreatment of peopleSystematic reviewAdvanced hybrid closed-loop systemBaseline glycemic levelsSelf-care burdenOptimization of outcomesContinuous glucose monitoring systemHybrid closed-loop systemAdvanced complicationsStandard careGlucose monitoring systemHypoglycemia riskGlycemic levelsGlycemic variabilityDiabetes therapyDiabetesHealthcare teamInsulin pumpType 1Glucose monitoringInsulin deliveryDevice initiationBehavioral modificationFurther studiesPsychosocial Outcomes with the Omnipod® 5 Automated Insulin Delivery System in Children and Adolescents with Type 1 Diabetes and Their Caregivers
Hood K, Polonsky W, MacLeish S, Levy C, Forlenza G, Criego A, Buckingham B, Bode B, Hansen D, Sherr J, Brown S, DeSalvo D, Mehta S, Laffel L, Bhargava A, Huyett L, Vienneau T, Ly T. Psychosocial Outcomes with the Omnipod® 5 Automated Insulin Delivery System in Children and Adolescents with Type 1 Diabetes and Their Caregivers. Pediatric Diabetes 2023, 2023: 1-12. DOI: 10.1155/2023/8867625.Peer-Reviewed Original ResearchType 1 diabetesGlycemic outcomesInsulin delivery systemsPsychosocial outcomesSleep qualityDiabetes-related distressCaregivers of childrenRegression analysisBaseline characteristicsDelivery systemProspective studyClinical trialsLinear regression analysisPsychosocial measuresParticipant characteristicsDiabetesCaregiversOutcomesOmnipodChildrenAdolescentsTrialsMonthsAdditional benefitSignificant improvement336-OR: Insulin Delivery Modality Does Not Impact Glycemic Change during Physical Activity in Youth with Type 1 Diabetes (T1D)—Results from the Real-World T1DEXI Pediatric Study
RIDDELL M, BERGFORD S, GAL R, PATTON S, CLEMENTS M, CALHOUN P, SHERR J. 336-OR: Insulin Delivery Modality Does Not Impact Glycemic Change during Physical Activity in Youth with Type 1 Diabetes (T1D)—Results from the Real-World T1DEXI Pediatric Study. Diabetes 2023, 72 DOI: 10.2337/db23-336-or.Peer-Reviewed Original ResearchInsulin delivery modalitiesPre-exercise glucoseJuvenile Diabetes Research FoundationPediatric studiesGlucose levelsDelivery modalitiesSpeakers bureauType 1 diabetesBlood glucose levelsInsulin delivery methodsNIH National InstituteAdvisory PanelGlycemic changesContinuous glucose monitorHarry B. Helmsley Charitable TrustPhysical activityExercise typeType 1Activity monitorDiabetesNovo NordiskEli LillyLeona M.Helmsley Charitable TrustT1D.CGM Metrics Identify Dysglycemic States in Participants From the TrialNet Pathway to Prevention Study.
Wilson D, Pietropaolo S, Acevedo-Calado M, Huang S, Anyaiwe D, Scheinker D, Steck A, Vasudevan M, McKay S, Sherr J, Herold K, Dunne J, Greenbaum C, Lord S, Haller M, Schatz D, Atkinson M, Nelson P, Pietropaolo M. CGM Metrics Identify Dysglycemic States in Participants From the TrialNet Pathway to Prevention Study. Diabetes Care 2023, 46: 526-534. PMID: 36730530, PMCID: PMC10020029, DOI: 10.2337/dc22-1297.Peer-Reviewed Original ResearchConceptsOral glucose tolerance testNormal oral glucose tolerance testType 1 diabetesDiabetes-related autoantibodiesGlucose levelsCGM metricsTrialNet PathwayPrevention StudyAbnormal oral glucose tolerance testGlucose valuesGlucose tolerance testContinuous glucose monitoring parametersStage 2 participantsRelatives of individualsCGMS assessmentDysglycemic statesTolerance testIdentification of individualsDiabetesNegative testAutoantibodiesProgressionBaseline dataIndividualsParticipants
2022
Automated insulin delivery: benefits, challenges, and recommendations. A Consensus Report of the Joint Diabetes Technology Working Group of the European Association for the Study of Diabetes and the American Diabetes Association
Sherr JL, Heinemann L, Fleming GA, Bergenstal RM, Bruttomesso D, Hanaire H, Holl RW, Petrie JR, Peters AL, Evans M. Automated insulin delivery: benefits, challenges, and recommendations. A Consensus Report of the Joint Diabetes Technology Working Group of the European Association for the Study of Diabetes and the American Diabetes Association. Diabetologia 2022, 66: 3-22. PMID: 36198829, PMCID: PMC9534591, DOI: 10.1007/s00125-022-05744-z.Peer-Reviewed Original ResearchConceptsAmerican Diabetes AssociationStudy of DiabetesDiabetes AssociationEuropean AssociationConsensus reportClinical careInsulin pumpInsulin deliveryIntensive insulin therapyType 1 diabetesManagement of diabetesRegulatory approvalContinuous glucose monitoringWorking GroupInsulin therapyInsulin delivery systemsDiabetesGlucose monitoringGlucose dataInternal review processAssociationSensor glucose dataCareReportGroupAutomated Insulin Delivery: Benefits, Challenges, and Recommendations. A Consensus Report of the Joint Diabetes Technology Working Group of the European Association for the Study of Diabetes and the American Diabetes Association.
Sherr JL, Heinemann L, Fleming GA, Bergenstal RM, Bruttomesso D, Hanaire H, Holl RW, Petrie JR, Peters AL, Evans M. Automated Insulin Delivery: Benefits, Challenges, and Recommendations. A Consensus Report of the Joint Diabetes Technology Working Group of the European Association for the Study of Diabetes and the American Diabetes Association. Diabetes Care 2022, 45: 3058-3074. PMID: 36202061, DOI: 10.2337/dci22-0018.Peer-Reviewed Original ResearchConceptsAmerican Diabetes AssociationStudy of DiabetesDiabetes AssociationEuropean AssociationConsensus reportClinical careInsulin pumpInsulin deliveryIntensive insulin therapyType 1 diabetesManagement of diabetesRegulatory approvalContinuous glucose monitoringWorking GroupInsulin therapyInsulin delivery systemsDiabetesGlucose monitoringGlucose dataInternal review processAssociationSensor glucose dataCareReportGroupWhen insulin isn’t enough: targeting glucagon in type 1 diabetes
Van Name M, Sherr J. When insulin isn’t enough: targeting glucagon in type 1 diabetes. Nature Medicine 2022, 28: 2007-2008. PMID: 36192555, DOI: 10.1038/s41591-022-02019-3.Commentaries, Editorials and LettersConsensus Recommendations for the Use of Automated Insulin Delivery Technologies in Clinical Practice
Phillip M, Nimri R, Bergenstal RM, Barnard-Kelly K, Danne T, Hovorka R, Kovatchev BP, Messer LH, Parkin CG, Ambler-Osborn L, Amiel SA, Bally L, Beck RW, Biester S, Biester T, Blanchette JE, Bosi E, Boughton CK, Breton MD, Brown SA, Buckingham BA, Cai A, Carlson AL, Castle JR, Choudhary P, Close KL, Cobelli C, Criego AB, Davis E, de Beaufort C, de Bock MI, DeSalvo DJ, DeVries JH, Dovc K, Doyle FJ, Ekhlaspour L, Shvalb NF, Forlenza GP, Gallen G, Garg SK, Gershenoff DC, Gonder-Frederick LA, Haidar A, Hartnell S, Heinemann L, Heller S, Hirsch IB, Hood KK, Isaacs D, Klonoff DC, Kordonouri O, Kowalski A, Laffel L, Lawton J, Lal RA, Leelarathna L, Maahs DM, Murphy HR, Nørgaard K, O’Neal D, Oser S, Oser T, Renard E, Riddell MC, Rodbard D, Russell SJ, Schatz DA, Shah VN, Sherr JL, Simonson GD, Wadwa RP, Ward C, Weinzimer SA, Wilmot EG, Battelino T. Consensus Recommendations for the Use of Automated Insulin Delivery Technologies in Clinical Practice. Endocrine Reviews 2022, 44: 254-280. PMID: 36066457, PMCID: PMC9985411, DOI: 10.1210/endrev/bnac022.Peer-Reviewed Original ResearchConceptsInsulin delivery technologiesGlycemic goalsNear-normal glucose levelsLong-term complicationsReal-world studyHypoglycemia riskDiabetes QualityConsensus recommendationsGlucose levelsGlobal prevalenceDiabetes managementEligibility criteriaClinical practiceDelivery technologiesHealthcare providersClinical settingDiabetesInsurance coverageSignificant proportionCliniciansAid successPWDPayersComplicationsTremendous advancesHow introduction of automated insulin delivery systems may influence psychosocial outcomes in adults with type 1 diabetes: Findings from the first investigation with the Omnipod® 5 System
Polonsky WH, Hood KK, Levy CJ, MacLeish SA, Hirsch IB, Brown SA, Bode BW, Carlson AL, Shah VN, Weinstock RS, Bhargava A, Jones TC, Aleppo G, Mehta SN, Laffel LM, Forlenza GP, Sherr JL, Huyett LM, Vienneau TE, Ly TT, Group F. How introduction of automated insulin delivery systems may influence psychosocial outcomes in adults with type 1 diabetes: Findings from the first investigation with the Omnipod® 5 System. Diabetes Research And Clinical Practice 2022, 190: 109998. PMID: 35853530, PMCID: PMC10901155, DOI: 10.1016/j.diabres.2022.109998.Peer-Reviewed Original ResearchConceptsType 1 diabetesPsychosocial outcomesTreatment satisfactionInsulin delivery systemsSleep qualityPsychosocial measuresParticipant characteristicsBaseline participant characteristicsDiabetes distressGlycemic outcomesProspective safetyEfficacy studiesLinear regression analysisDelivery systemAid useAdultsOutcomesOmnipodT1D.DiabetesRegression analysisMonthsSignificant improvementDistressMulticenter765-P: Glycemic Outcomes across Total Daily Insulin Doses with the Omnipod 5 Automated Insulin Delivery System (AID) among People with Type 1 Diabetes (T1D) Ages 2 to 70 Years
SCHOELWER M, BODE B, CARLSON A, CRIEGO A, FORLENZA G, WEINSTOCK R, HANSEN D, BUCKINGHAM B, MEHTA S, LAFFEL L, SHERR J, LEVY C, HIRSCH I, MACLEISH S, DESALVO D, SHAH V, BHARGAVA A, JONES T, ALEPPO G, GURLIN R, LY T. 765-P: Glycemic Outcomes across Total Daily Insulin Doses with the Omnipod 5 Automated Insulin Delivery System (AID) among People with Type 1 Diabetes (T1D) Ages 2 to 70 Years. Diabetes 2022, 71 DOI: 10.2337/db22-765-p.Peer-Reviewed Original ResearchDaily insulin doseMannKind CorporationInsulin doseGlycemic outcomesEvaluate glycemic outcomesHigher TIRNational Institute of DiabetesDigestive and Kidney DiseasesCenter for Health ResearchType 1 diabetesEli Lilly and CompanySpeakers bureauInsulin requirementsAid useKidney diseaseInsulin needsMannKindCohort of peopleMedtronicTherapy phaseAged 2Janssen PharmaceuticalsOlder ageDiabetesT1D100-LB: Glycemic Control Using Recommended Settings in Youth and Adults with Type 1 Diabetes (T1D) —Minimed 780G System with the Calibration-Free Guardian 4 Sensor Results
VIGERSKY R, BODE B, BRAZG R, BUCKINGHAM B, CARLSON A, KAISERMAN K, KIPNES M, LILJENQUIST D, PHILIS-TSIMIKAS A, PIHOKER C, POP-BUSUI R, REED J, SHERR J, SHULMAN D, SLOVER R, THRASHER J, CHEN X, LIU M, CORDERO T, VELLA M, RHINEHART A, SHIN J. 100-LB: Glycemic Control Using Recommended Settings in Youth and Adults with Type 1 Diabetes (T1D) —Minimed 780G System with the Calibration-Free Guardian 4 Sensor Results. Diabetes 2022, 71 DOI: 10.2337/db22-100-lb.Peer-Reviewed Original ResearchMannKind CorporationSpeakers bureauKidney diseaseNovo NordiskEli LillyAdvisory PanelNational InstituteHealth researchMonths of useEffectiveness endpointReata PharmaceuticalsGlycemic controlPivotal trialsSevere hypoglycemiaEffectiveness outcomesGlycemic metricsDiabetesBayer AGHealth groupsRoche DiagnosticsUnitedHealth GroupLexicon PharmaceuticalsMiniMedTarget rangeSanofiClinical Implementation of the Omnipod 5 Automated Insulin Delivery System: Key Considerations for Training and Onboarding People With Diabetes
Berget C, Sherr JL, DeSalvo DJ, Kingman RS, Stone SL, Brown SA, Nguyen A, Barrett L, Ly TT, Forlenza GP. Clinical Implementation of the Omnipod 5 Automated Insulin Delivery System: Key Considerations for Training and Onboarding People With Diabetes. Clinical Diabetes 2022, 40: 168-184. PMID: 35669307, PMCID: PMC9160549, DOI: 10.2337/cd21-0083.Peer-Reviewed Original ResearchInsulin delivery systemsDiabetes specialty clinicPrimary care providersPrimary care settingContinuous glucose monitoring systemTherapeutic burdenDelivery systemGlucose monitoring systemDiabetes careSpecialty clinicCare settingsCare providersDiabetesInsulin pumpInsulin deliveryClinical implementationGlycemic dataGlycemiaClinicTherapyAid technologyCliniciansCare
2021
Continuous glucose monitoring use and glucose variability in very young children with type 1 diabetes (VibRate): A multinational prospective observational real‐world cohort study
Dovc K, Van Name M, Bizjan B, Rusak E, Piona C, Yesiltepe‐Mutlu G, Mentink R, Frontino G, Macedoni M, Ferreira SH, Serra‐Caetano J, Galhardo J, Pelicand J, Silvestri F, Sherr J, Chobot A, Biester T, Group F. Continuous glucose monitoring use and glucose variability in very young children with type 1 diabetes (VibRate): A multinational prospective observational real‐world cohort study. Diabetes Obesity And Metabolism 2021, 24: 564-569. PMID: 34820985, PMCID: PMC9306649, DOI: 10.1111/dom.14607.Peer-Reviewed Original Research717-P: Real-World, Patient-Reported Data on Training and Use of 670G Hybrid Closed-Loop (HCL) among Children and Adults with Type 1 Diabetes (T1D)
BAUZA C, DUBOSE S, VERDEJO A, BECK R, BERGENSTAL R, SHERR J. 717-P: Real-World, Patient-Reported Data on Training and Use of 670G Hybrid Closed-Loop (HCL) among Children and Adults with Type 1 Diabetes (T1D). Diabetes 2021, 70 DOI: 10.2337/db21-717-p.Peer-Reviewed Original ResearchAdjunctive Therapies for Type 1 Diabetes
Nally L, Van Name M, Tamborlane W, Sherr J. Adjunctive Therapies for Type 1 Diabetes. Contemporary Endocrinology 2021, 143-150. DOI: 10.1007/978-3-030-64133-7_13.Chapters
2020
Incident diabetes complications among women with type 1 diabetes based on parity
Polsky S, Foster NC, DuBose SN, Agarwal S, Lyons S, Peters AL, Uwaifo GI, DiMeglio LA, Sherr JL, Levy CJ. Incident diabetes complications among women with type 1 diabetes based on parity. The Journal Of Maternal-Fetal & Neonatal Medicine 2020, 35: 4629-4634. PMID: 33280471, DOI: 10.1080/14767058.2020.1858278.Peer-Reviewed Original ResearchConceptsType 1 diabetesParous womenNulliparous womenDiabetes complicationsRisk factorsHigher body mass indexAdverse lipid profileTriglyceride/HDLOverweight/obesityBody mass indexAdvanced nephropathyMass indexT1D ExchangeFirst pregnancyPregnant womenChildbirth QuestionnaireLipid profileCardiovascular diseaseComplicationsWomenHypertensionYear 5Further studiesSignificant differencesDiabetesGlucagon Administration by Nasal and Intramuscular Routes in Adults With Type 1 Diabetes During Insulin-Induced Hypoglycaemia: A Randomised, Open-Label, Crossover Study
Suico JG, Hövelmann U, Zhang S, Shen T, Bergman B, Sherr J, Zijlstra E, Frier BM, Plum-Mörschel L. Glucagon Administration by Nasal and Intramuscular Routes in Adults With Type 1 Diabetes During Insulin-Induced Hypoglycaemia: A Randomised, Open-Label, Crossover Study. Diabetes Therapy 2020, 11: 1591-1603. PMID: 32514794, PMCID: PMC7324463, DOI: 10.1007/s13300-020-00845-7.Peer-Reviewed Original ResearchEffect of Exercise and Meals on Continuous Glucose Monitor Data in Healthy Individuals Without Diabetes
DuBose SN, Li Z, Sherr JL, Beck RW, Tamborlane WV, Shah VN. Effect of Exercise and Meals on Continuous Glucose Monitor Data in Healthy Individuals Without Diabetes. Journal Of Diabetes Science And Technology 2020, 15: 593-599. PMID: 32064911, PMCID: PMC8120054, DOI: 10.1177/1932296820905904.Peer-Reviewed Original ResearchConceptsEffects of exerciseSensor glucose levelsHealthy individualsResistance exerciseNadir glucoseGlucose levelsNonobese body mass indexT1D Exchange Clinic NetworkPeak postprandial glucoseBody mass indexGlucose concentrationTime of mealsNadir glucose concentrationsConsumption of alcoholMass indexPostprandial glucoseNonexercise dayAerobic exerciseExercise dayClinic networkMean changeFuture therapiesDiabetesDexcom G6Glucose monitor data